rezulin
Pharmaranks rates Rezulin 3.0/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Rezulin (Troglitazone) is a medication used to treat Type 2 Diabetes Mellitus.
Troglitazone · by Pfizer
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Troglitazone
- Form
- Tablet
- Strength
- Troglitazone 200MG · Troglitazone 300MG · Troglitazone 400MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- type 2 diabetes mellitus
- Manufacturer
- Pfizer
- FDA application
- NDA020720
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Rezulin treat?
- Rezulin (Troglitazone) may be used to treat type 2 diabetes mellitus, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Rezulin rated?
- pharmaranks gives Rezulin a composite score of 3.0 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Rezulin?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Rezulin. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Rezulin?
- Rezulin is marketed by Pfizer. You can see Pfizer's full profile, rating, and other products on pharmaranks.
- Is Rezulin a brand-name or generic drug?
- Rezulin is a brand-name product with the active ingredient Troglitazone.
- Is Rezulin available over the counter?
- No. Rezulin is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Rezulin come in?
- Rezulin is currently marketed as tablet, per the FDA's National Drug Code Directory.
- Is Rezulin FDA-registered?
- Rezulin is on record with the U.S. FDA under application number NDA020720. You can verify this on its official FDA label.
- Has Rezulin been recalled by the FDA?
- Rezulin has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Rezulin safe?
- There's no single safe-or-not verdict. pharmaranks gives Rezulin a recall-safety score of 60/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about TROGLITAZONE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 62 reports naming TROGLITAZONE — the active ingredient in Rezulin, and the FDA flagged 82% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- pulmonary oedema9 reports
- renal failure9 reports
- acidosis8 reports
- hepatic failure8 reports
- acute kidney injury7 reports
- diabetes mellitus inadequate control7 reports
- pneumonia7 reports
- renal failure acute7 reports
Read these as a signal, not a rate. A report does not mean TROGLITAZONE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
brynovin
Sitagliptin Hydrochloride
invokana
Canagliflozin
merilog
Insulin Aspart-Szjj
merilog solostar
Insulin Aspart-Szjj
rezvoglar
Insulin Glargine-Aglr
tradjenta
Linagliptin
Compare Rezulin head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
rezulin
60/100